Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, discovers and develops programmed cellular immunotherapies for cancer and immune disorders in the United States. Its novel ex vivo cell programming approach applies to modulate the therapeutic function and direct the fate of immune cells. The company's lead product candidate is ProTmune, a programmed immuno-regulatory cell therapy that is in clinical development stage for the prevention of acute graft-versus-host disease and cytomegalovirus infection in immunocompromised patients undergoing allogeneic hematopoietic cell transplantation. Its preclinical programs include NK- and T-cell cancer immunotherapies, such as off-the-shelf therapies derived from engineered induced pluripotent cells comprising iNK cell therapy and iT cell therapy; and a CD34+ cell immuno-regulatory therapy to suppress aberrant auto-reactive effector cells for autoimmune diseases. The company has a research collaboration and license agreement with Juno Therapeutics, Inc. to identify and apply small molecule modulators to enhance the therapeutic function of genetically-engineered chimeric antigen receptor T-cell and T-cell receptor immunotherapies. It has a partnership agreement with Memorial Sloan Kettering Cancer Center for the development of off-the-shelf T-cell product candidates using engineered pluripotent cell lines; and an immunotherapy collaboration with the University of Minnesota. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California. Full Profile http://finance.yahoo.com/quote/FATE/profile?p=FATE Home page http://www.fatetherapeutics.com Statistic http://finance.yahoo.com/quote/FATE/key-statistics?p=FATE Holders http://finance.yahoo.com/quote/FATE/holders?p=FATE Yahoo news http://finance.yahoo.com/quote/FATE/?p=FATE
At close: March 9 $4.54+0.46 (+11.27%) Market Cap 187.89M Day's Range 4.07 - 4.58 52 Week Range 1.47 - 4.75 Volume 774,630 Avg. Volume 228,748 Resist. 4.75 - 5.55 sup. 4.14 (pivot) - 3.49 - 2.71 they announced today that the Company will host a conference call and live audio webcast on Thursday, March 16, 2017 at 5:00 p.m. ET to report its fourth quarter and full year 2016 financial results and provide a corporate update. IMO watch that resistance to see where it goes ..... yesterday maybe someone already know hoe the results would be
Fate Therapeutics, Inc. (FATE) closed 4.80+0.26 (+5.73% Day's Range 4.50 - 5.25 52 Week Range 1.47 - 5.25 Volume 1,584,985 Avg. Volume 228,768 Resist. now 5.24 - 6.13 Hi longtbul easy to answer that today I already know how they close however they had another good day testing the 5.25 resistance but didn't brake it and closed on the VWAP seen the volume increases I would say some more stock up for next week (result) yesterday reange IMO is where we have to look on Monday I still look at them as a scalp-day trade .. don't know the stock enough as it is a "new entry"
Fate Therapeutics Announces FDA Clearance of Investigational New Drug Application for FATE-NK100 Natural Killer Cell Cancer Immunotherapy http://finance.yahoo.com/news/fate-therapeutics-announces-fda-clearance-120000379.html in pre doing well high 5.68 (Friday close 4.80)